強直性脊椎炎に注目した脊椎関節炎の新規治療
Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283
This review aimed to discuss the emerging agents for the treatment of axSpA.
It details safety data on filgotinib, highlighting that sperm toxicity does not appear to be a concern. It was concluded that combining agents targeting TNFa and IL-187 and/or JAK needs further investigation and may hold the key to assisting the large body of patients with inflammatory rheumatic conditions not achieving remission
Keywords:
